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Impact of CMV PCR Blips in Recipients of
Solid Organ and Hematopoietic Stem Cell
Transplantation
Isabelle P. Lodding, MD,1 AmandaMocroft, PhD,2 Caspar da Cunha Bang,MD, PhD,3 Finn Gustafsson, MD, PhD,4
Martin Iversen, DMSc, MD,5 Nikolai Kirkby, PhD,6 Michael Perch, MD,5 Allan Rasmussen, MD,7
Henrik Sengeløv, MD,3 Søren S. Sørensen, MD,8 and Jens D. Lundgren, MD1
Background.Viral blips reflecting polymerase chain reaction (PCR) artefacts or transient low-level replication are well described
in the human immunodeficiency virus setting. However, the epidemiology of such blips in transplant recipients screened for cyto-
megalovirus (CMV) with PCR remains uncertain and was investigated in a cohort of solid organ and hematopoietic stem cell
recipients. Methods. Eligible recipients had known donor/recipient CMV IgG serostatus, and 3 CMV PCRs ≥. The CMV
PCR triplicates (3 consecutive CMV PCRs) were defined; the first CMV PCR was always negative, and the time between
the second and third samples was 7 days ≤. A positive second but negative third sample represented a blip. Odds ratio
(OR) for factors associated with a triplicate being a blip was estimated by binomial regression adjusted for repeated measure-
ments. Whether blips affected the hazard ratio (HR) for subsequent CMV infection was determined with a Cox model.Results.
851 recipients generated 3883 CMV PCR triplicates. The OR of a triplicate representing a blip decreased with increasing viral load
of the second sample (vs 273 IU/mL; >273-910 IU/mL: odds ratio [OR], 0.2; 95% confidence interval [CI], 0.1-0.5; >910 IU/mL: OR,
0.08; 95% CI, 0.02-0.2; P ≤ 0.0002) and increased with intermediary-/low-risk serostatus (vs high risk) (OR, 2.8; 95% CI,
1.2-5.5; P = 0.01). Cumulative exposure to DNAemia in the CMV blips greater than 910 IU/mL indicated increased HR of sub-
sequent CMV infection (HR, 4.6; 95% CI, 1.2-17.2; P = 0.02). Conclusions. Cytomegalovirus blips are frequent; particu-
larly when the viral load of the first positive PCR is < 910 IU/mL, and serostatus risk is intermediary/low. Accumulating blips
suggest intermittent low-level replication. If blips are suspected, confirmation of ongoing replication before initiation of treat-
ment is prudent.
(Transplantation Direct 2018;4: e355; doi: 10.1097/TXD.0000000000000787. Published online 16 May, 2018.)
Posttransplant cytomegalovirus (CMV) infection remainsa serious complication to both solid organ transplantation
(SOT) and hematopoietic stem cell transplantation (HSCT).
Currently, 2 main strategies, or a hybrid hereof, are applied
with the aim to prevent CMV disease.1,2 Universal prophy-
laxis with valganciclovir for 3 to 12 months after transplan-
tation is typically used among SOT recipients (1), whereas
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the preemptive strategy consisting of screening with CMV
PCRand treatment in case of emergingCMVinfection is gen-
erally used for HSCT recipients and in SOT recipients after
valganciclovir prophylaxis is stopped.2
The indication for starting antiviral therapy in case of a
positive CMV PCR result remains to be defined. There are
2 issues to consider. Despite the recent introduction of aWorld
Health Organization (WHO) standard for CMV PCR,3 assay
variability remains which may generate false positive
values.4-7 Conversely, low-level positive reads may reflect
early signs of ongoing viral replication.8,8-10 Antiviral therapy
should only be initiated in the latter situation.
In the human immunodeficiency virus (HIV) setting,
screening with PCR technology is known to identify isolated
positive results, entitled “blips”.11-13 These blips may either
constitute a false positive read due to assay variability or
reflect transient low level viral replication. The implications
and consequences of HIV blips have hitherto been extensively
debated, even though many observations indicate they do
not reflect ongoing replication.11-15
In the field of CMV infection, the presence of solitary
CMV PCR reads or blips, as opposed to low-level CMV rep-
lication, has not previously been described. Here we report
their prevalence, risk factors, and biological implicationswhen
screening a large and unselected cohort of SOT and HSCT
recipients with extensive and complete follow-up.
MATERIAL AND METHODS
Definitions of the CMV PCR Triplicate, CMV Infection
and CMV blip
To investigate the frequency and impact of CMV blips, we
created a model named the CMV PCR triplicate. The CMV
PCR triplicate consist of 3 consecutive samples, with 7 days
or less between the second (indicator sample) and the third
(response sample) CMV PCRs. All available CMV PCRs
were considered for inclusion, and there are 3 different types
of triplicates (Figure 1):
• The negative CMV triplicates (controls), in which all CMV
PCR samples in the triplicate were negative.
• The CMV infection triplicates, in which the first CMV PCR
sample was negative, but the second (indicator) and third (re-
sponse) CMV PCR samples were positive; this combination
indicates CMV infection (ie, CMV infection is defined as ≥2
consecutive CMV PCRs ≥ 273 IU/mL taken within 7 days
of each other).
• The CMVblips triplicates, in which the first CMVPCR sample
is negative, the second (indicator) CMVPCR sample is positive,
but the third (response) CMV PCR sample is negative. This
combination is classified as a CMV blip.
If the third value (response value) in the triplicate was neg-
ative (relevant for controls and blips), it could also be used as
the first value in a subsequent triplicate, assuming all other
inclusion criteria were met.
Patients
The SOT and HSCT recipients registered in the Manage-
ment of Posttransplant Infections in Collaborating Hospitals
(MATCH) program16 between January 1, 2010, and August
14, 2015 (n = 1,512) were considered for inclusion. All CMV
PCR’s performed within the first 12 months following trans-
plantation were investigated. The CMV IgG serostatus of
donor (D)/recipient (R) (positive (+)/negative (−)) were de-
termined before transplantation, and the eligible combi-
nations for inclusion into the study were D+/R−, D+/R+
or D−/R+ (n = 1142). Furthermore, the recipients needed
to have ≥3 CMV PCR analyses fulfilling the CMV tripli-
cate definition previously described to be included in the
study (n = 851).
Management of CMV
In general, the SOT recipients (heart, lung, liver, and kidney
recipients) receive valganciclovir prophylaxis for 3 months
after transplantation. During this time, the patients were
monitored monthly with CMV PCR. Upon cessation of
valganciclovir prophylaxis, the patients were monitored weekly
FIGURE 1. Definition of the CMV PCR triplicate, and the different outcomes. The CMV PCR triplicate consist of 3 consecutive samples,
with ≤ 7 days between the second (index sample) and the third (response sample) CMV PCRs. There are 3 different outcomes of this
model: (1) negative control triplicates, were all 3 CMV PCRs in the triplicate are negative; (2) CMV triplicates indicating CMV infection were both
the indicator and response sample are positive; (3) CMV triplicates indicatingCMVblips, where the indicator sample being the only positive sample.
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with CMV PCR during month 4 to 6 posttransplant, and
finally monthly until 1 year posttransplant. In case of a de-
tected CMV infection, the patients were treated preemptively
with valganciclovir and monitored weekly until 2 consecutive
negative CMV PCR samples.
The HSCT recipients (myeloablative conditioning trans-
plantation (MAC), nonmyeloablative conditioning (NMA)
and umbilical cord blood [UCB] recipients) weremonitored with
CMV PCRweekly from week 4 to week 17 posttransplant, and
then at weeks 19, 26, and 62. In case of graft-versus-host disease,
weekly monitoring was continued. Emerging CMV infections
were treated preemptively with valganciclovir.
In case ofmyelosuppression or resistance toward valganciclovir,
both SOTand HSCT recipients were treated with foscovir.17
The CMV PCRs in the monitoring programs were per-
formed on plasma. The COBAS Amplicor kit was used at
our center throughout 2011 and was then discontinued. Since
the beginning of 2011, the COBAS AmpliPrep/COBAS
TaqMan was introduced as its substitute.18 Through simulta-
neous testing of the 2 different CMV PCR kits during 2011,
they were found to be equivalent (conversion factor 1:1).
We have converted all CMV viral loads in the present
study into IU/mL using the conversion factor for the COBAS
AmpliPrep/COBAS TaqMan (1 copy/mL corresponding to
0.91 IU/mL). The lower limit of quantification of the CMV
PCR kit used is 273 IU/mL.
The recipients were stratified according to risk of CMV in-
fection as high, intermediary, or low risk, based on the Donor
(D) and Recipient (R) CMV IgG serostatus.19,20 The high-
risk group constituted of D+/R− SOT and D−/R+ HSCT re-
cipients. D+/R+ constituted the intermediary risk group for
both types of transplantations, and the low risk group D−/R
+ for SOT and D+/R− for HSCT. Because of the low number
of positive CMV PCR triplicates that originates from low risk
patients (n = 25, 6%of the 411 positiveCMVPCR triplicates),
these are grouped together with the intermediary group.
For all positive CMV triplicates, administration of anti-
CMV treatment in relation to the triplicate was registered
as either starting before the indicator sample, at or after the
indicator sample but before the response sample, or no treat-
ment administered in relation to the CMV PCR triplicate
(Figure 1).
Statistical Analyses
Baseline clinical characteristics and features of the included
patients were described using standard descriptive statistics.
Each included patient could be the cause of multiple CMV
triplicates with different outcomes (negative control, CMV
infection or CMV blip). The overall proportion of first-time
blips in the cohort was calculated and stratified into 3 groups
depending on the viral load in the indicator sample (Figures 1
and 2). This model was also stratified according to type of
transplantation and risk of CMV infection according to D/R
CMV IgG serostatus.
The odds ratio (OR) of the first positive CMVPCRbeing a
CMV blip (ie, only CMV PCR triplicates with positive indi-
cator samples, and only the first triplicate per patient) was
modeled using logistic regression, investigating potential
explanatory variables such as age, sex, calendar year, type
of transplantation, risk of CMV infection, CMV viral load
in the first positive sample, and administration of anti-CMV
treatment between the first positive sample and the succeeding
sample. Year of transplant and use of anti-CMV treatment
were highly correlated and hence only use of anti-CMV treat-
ment was included to avoid collinearity in the final model.
The analyses were repeated using all triplicates where the
indicator sample was positive (ie, more than 1 triplicate per
person), using binomial regression and adjusting for repeated
measurements within patients.
Multivariate Cox regression was used to explore if CMV
blips are a predictor of subsequent CMV infection. The model
was adjusted for relevant covariates such as age, sex, calendar
year, type of transplantation and CMV IgG serostatus. Patient
follow-up was censored at the earliest of (1) 365 days
posttransplant, (2) August 14 2015, for patients transplanted
after the 14th of August 14, 2014; (3) 28 days after the last
CMV PCRwithin the 1st year posttransplant, 4) death within
the 1st year posttransplant or 5) CMV infection. Age at
FIGURE 2. Flowchart of CMV triplicates and corresponding transplant recipients. *By definition, these 80 recipients have a blip before CMV
infection or no CMV infection.
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transplantation was divided into 2 categories: ≤ 16 years,
>16 years. CMV blips were included as a time dependent var-
iable. Death was included in the model as a competing risk.
First, we modelled the impact of the first CMV blip on
CMV infection. The model was then repeated looking at
the impact on CMV infection of repeated CMV blips as
well as the impact of cumulative CMV viral load in blips
(ie, the total viral load experienced in any blip/s occurring
before CMV infection in each patient). Based on the ob-
served viral load of the CMV blips, different viral load
cut-offs were tested. Due to power, the final model fo-
cused at cumulative viremia of the blips ≤910 IU/mL
and >910 IU/mL.
Two-sided P values were used for all analyses, and results
were considered statistically significant at a level of 0.05 or
less. The statistical analyses were performed using SAS 9.4
(SAS Institute, Cary, NC).
RESULTS
Patient Characteristics
A total of 851 patients had at least 1 CMV PCR triplicate
that fitted 1 of the outcomes described in Figure 1. When
comparing these 851 included patients with the 661 excluded
patients, age and sex were comparable (P > 0.3). Among the
excluded patients, the proportion of SOTrecipients was signif-
icantly higher compared to the included patients (P < 0.001).
Because these patients were excluded either due to missing
serostatus, or being CMV IgG D−/R−, or because they
did not fulfil the CMV PCR triplicate criteria, serostatus
and screening with CMV PCR were not comparable with the
included patients.
Of the 851 included patients, 476 (56%) constituted SOT
recipients and 375 (44%) constituted HSCT recipients. Most
patients were recipients of kidney transplantation (28% of
the transplantations), closely followed by MAC and NMA
transplantations (23% and 19%, respectively) (Table 1). Heart
and UCB transplantations only represented 4% and 2% of the
patients, respectively.
Age and sex were similarly distributed among the 2
groups of recipients (Table 1), although the HSCT recipi-
ents tended to be younger compared with the SOT recipi-
ents (P = 0.05).
Risk profiling (high and intermediate/low risk; seemethods)
based onD/RCMV IgG serostatus pretransplantation differed
somewhat between SOT and HSCT recipients, with a higher
proportion of high-risk serostatus recipients in the HSCT
group (P < 0.0001) (Table 1).
CMV PCR Triplicates
In total, the recipients generated 3883 CMV PCR tripli-
cates (Figure 2). 1269 of these came from the 476 (33%)
SOT recipients and the remaining 2614 (67%) were gen-
erated by the 375 HSCT recipients. The majority (3472/
3883 [89%; 95% confidence interval [CI], 88-90]) of the
CMV PCR triplicates were negative controls, a distribution
TABLE 1.
Characteristics of 851 transplant recipients generating a total of 3,883 CMV PCR triplicates
Characteristics Total, N = 851 SOT, n = 476 HSCT, n = 375 P a
Baseline demographics
Median age (IQR), y 48 (32-59) 49 (37-58) 47 (22-61) 0.05
Male sex (%) 504 (59) 278 (58) 226 (60) 0.6
Risk of CMV infection according to CMV IgG status b
High risk of CMV infection 276 (32%) 123 (26%) 153 (41%) <0.0001
Intermediary/low risk of CMV infection 575 (68%) 353 (74%) 222 (59%) <0.0001
Type of transplantation (%)
Heart 33 (4) 33 (7) —
Lung 108 (13) 108 (23) —
Liver 95 (11) 95 (20 —
Kidney 240 (28) 240 (50) —
MAC 198 (23) — 198 (53)
NMA 163 (19) — 163 (43)
UCB 14 (2) — 14 (4)
No. patients with a first CMV infection c (%) 233 (27; 95% CI, 24-30) 114 (24; 95% CI, 20-28) 119 (32; 95% CI, 27-36) 0.01
CMV PCR triplicates
Total amount of CMV PCR triplicates 3883 (100) 1269 (33; 95% CI, 31-34) 2614 (67; 95% CI, 66-69) <0.0001
No. negative controls (% of total amount of CMV triplicates) 3472 (89; [95% CI, 88-90]) 1092 (86; [95% CI, 84-88]) 2380 (91; [95% CI, 90-92]) <0.0001
No. CMV triplicates representing CMV infection
(% of total amount of CMV triplicates)
307 (8; 95% CI, 7-9) 140 (11 [95% CI, 9-13]) 167 (6; 95% CI, 5-7) <0.0001
No. blips (% of blips out of total amount of CMV triplicates) 104 (3; 95% CI, 2-3) 37 (3; 95% CI, 2-4) 67 (3; 95% CI, 2-3) 0.5
Description of baseline features of the 851 included patients, constituting the total number of 3883 CMV PCR triplicates.
a P value describes SOT vs HSCT.
b Risk of CMV infection according to D/R CMV IgG serostatus (+/-) at the time of transplantation. For solid organ transplantation recipients D+/R- is associated with high risk of CMV infection, whereas D-/R+ is
associated with low risk. Among bone marrow transplant recipients, D-/R+ is associated with a high risk of CMV infection, whereas D+/R- is associated with a low risk. For both types of transplantation, D+/R+ is
associated with intermediary risk of CMV infection. Because of the low number of patients in the low risk group, these patients are analysed together with the intermediate group.
c CMV infection defined as 2 consecutive CMV PCRs ≥273 IU/mL taken within 7 days of each other.
IQR, interquartile range; SOT, solid organ transplantation.
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that also was found when stratifying for type of transplanta-
tion, even though the proportion was significantly higher
amongHSCT recipients (Table 1). Of the remaining 411 pos-
itive CMV PCR triplicates, 307 (8%; 95% CI, 7-9) repre-
sented CMV infections and 104 (3%; 95% CI 2-3)
represented CMVblips (Figure 3). Of the 307CMVinfection
triplicates, 233 were first time infections and the remaining
74 constituted recurrent infection/s. Thus, of the 851 in-
cluded patients, 233 (27%; 95%CI, 24-30) developed a first
episode of CMV infection (Table 1 and Figure 2).
Out of the 104 CMV PCR triplicates representing CMV
blips, 53 were first-time blips that occurred before CMVinfec-
tion. The remaining 51CMVblips could either be a secondary
blip situated any time between the first blip and any potential
subsequent CMV infection/s, or they occurred after a CMV
infection (Figure 2).
CMV Blips in First Positive Triplicate
The first positive CMV PCR triplicate (n = 273) of each
patient were stratified into 3 different groups depending on
the CMV viral load in the first positive indicator CMV PCR
sample (Figure 3). The proportion of blips was lower the
higher the viral load of the first positive indicator CMV PCR
sample of the triplicate, and decreased with increasing viral
load. This pattern also persisted after stratifying for type of
transplantation and risk associated with CMV IgG serostatus
(Figure 3).
FIGURE 3. Distribution of CMV blips according to the viral load in the first positive (indicator) CMV PCR* and stratified for type of trans-
plantation and donor/recipients CMV IgG serostatus. For solid organ transplantation recipients D+/R- is associated with high risk of CMV
infection, while D-/R+ is associated with low risk. Among bone marrow transplant recipients, D-/R+ is associated with a high risk of CMV
infection, whereas D+/R- is associated with a low risk. For both types of transplantation, D+/R+ is associated with intermediary risk of
CMV infection. Due to the low number of patients in the low-risk group, these patients are analysed together with the intermediate group.
Fractional numbers to the right of the bars indicate the number of triplicates representing a CMV blip within each viral load interval. *Negative
control CMV PCR triplicates are not included in the figure.
TABLE 2.
The OR of the first positive indicator CMV PCR a being a CMV blip
Univariate Multivariate b
Factors OR (95% CI) P OR (95% CI) P
Use of anti-CMV treatment in relation to the CMV PCR triplicate
No treatment Reference Reference
Treatment initiated before the indicator sample 0.2 0.05-1.2 0.06 0.4 0.07-1.8 0.2
Treatment initiated between indicator and response samples 1.1 0.6-2.1 0.6 1.8 0.8-3.7 0.1
Risk associated with CMV IgG serostatus of donor and recipient
High risk Reference Reference
Intermediary/low risk 3.0 1.6-5.8 0.0009 2.8 1.2-5.5 0.01
Viral load of the indicator CMV PCR in the CMV PCR triplicate (IU/mL)
= 273 c Reference Reference
> 273-910 0.2 0.1-0.5 <0.0001 0.2 0.1-0.5 0.0002
> 910 0.08 0.03-0.2 <0.0001 0.08 0.02-0.2 <0.0001
The OR of the first positive indicator CMV PCR being a CMV blip.
a For each patient with a positive CMV PCR triplicate (273 patients), the odds of the first positive CMV PCR/patient being a CMV blip, and not an infection, was modelled using logistic regression. Thus, only
273/411 positive triplicates representing triplicates where the indicator sample of the triplicate is the first positive sample were included in this model. Repeating the model using all the 411 triplicates and
adjusting for repeated measurements did not change the results.
b Factors included in the table are selected using multivariate logistic regression. Other factors included in the models were: age, sex, type of transplantation (SOT vs HSCT).
c 273 IU/mL is the lower limit of quantification for the used CMV PCR kit.
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The OR of the first positive indicator CMV PCR being a
CMV blip rather than CMV infection was modelled for the
273 patients with first positive CMV PCR triplicates
(Table 2). Given that the indicator CMV PCR in the tripli-
cate was positive (and therefore that the outcome is either a
blip or CMVinfection), the odds of experiencing a CMVblip
were almost 3 times higher in recipients with intermediary/
low risk serostatus (OR, 2.8; 95% CI, 1.2-5.5; P = 0.01) in
their first triplicate than recipients with high-risk serostatus.
Furthermore, the odds of the triplicate being a CMV PCR blip
decreased markedly the higher the viral load of the indicator
sample measurement in the triplicate (Table 2). Use of anti-
CMV medication within the duration of the triplicate did
not predict whether the triplicate was a blip or an infection
(P≥ 0.1); additionally, sensitivity analyses using only triplicates
were no treatment had been initiated between the indicator and
response samples provided similar results (data not shown).
However, when comparing the viral load of the indicator sam-
ple between triplicates were treatment was initiated versus no
treatment administered in relation to the CMV PCR triplicate,
the viral load of the indicator sample was significantly higher
among triplicates were treatment was initiated (P < 0.0001).
Using the data from all the 411 positive CMV PCR tripli-
cates, the findingsmade for the first positive triplicate persisted
(see Table S1, http://links.lww.com/TXD/A83).
Impact of CMV Blips on CMV Infection
The unadjusted hazard of subsequent CMV infection
when comparing a single CMV blip before CMV infection
with no blip was 1.8 (95%CI, 1.02-3.2; P = 0.04). However,
this signal disappeared after adjustment (hazard ratio [HR],
1.46; 95% CI, 0.8-2.6), P = 0.2). When modelling the num-
ber of CMV blips before CMV infection, patients with ≥2
CMV blips had an increased hazard of CMV infection (HR,
2.8; 95% CI, 1.01-7.7; P = 0.05) when compared with no
blips, whereas no increased hazard was detected for patients
with only 1 blip (HR, 1.2; 95% CI, 0.6-2.4; P = 0.6). How-
ever, these estimates became nonsignificant when adding
death as a competing risk to the model. This prompted us to
investigate the cumulative exposure to viremia in the blips,
as presented in the final model (Figure 4). Factors associated
with significantly increased risk of CMV infection were:
recipients of either lung transplantation (HR, 1.5; 95% CI,
1.03-2.3), P = 0.03) or UCB transplantation (HR, 4.3; 95%
CI, 1.6-12.0), P = 0.004), high-risk serostatus (HR, 3.0;
95% CI, 2.3-4.0), P < 0.0001), and a cumulative viral
load > 910 IU/mL in CMV blips preceding CMV infection
(HR, 4.6; 95% CI, 1.2-17.2; P < 0.02).
DISCUSSION
In this study, we demonstrate that CMV blips occur in ap-
proximately 19% (53/273) of the first positive CMV PCR
samples obtained while screening SOT and HSCT recipients
with CMV PCR. The CMV blips are particularly frequent
if the viral load of the first positive PCR (the indicator sample
in Figure 1) is at the detection limit or if the patient has inter-
mediary/low risk serostatus. Furthermore, the cumulative viral
load of CMV blips influence the risk of CMV infection, sug-
gesting that these blips at least partly reflect low-level viremia
rather than merely intermittent false positive results caused
by the technology. Thus, the characteristics of CMV blips are
important markers for subsequent infection. Upon detection
of a first positive CMV PCR, these observations should be
carefully considered by the clinician before initiation of
anti-CMV treatment.
The term “viral blips” is well knownwithin the HIV setting
and entails detection of episodes of transient HIV viremia in
patients who are considered suppressed on combined antire-
troviral therapy.11-13 Through the years, the interpretation of
HIV blips has been discussed extensively. A number of hy-
potheses have been suggested to explain this observation in-
cluding random statistical and biological variation around
mean viral loads,11 assay variations and artefacts of the PCR
technology,21 poor adherence of the patient,12 and emerging
drug resistance.22 However, a clear definition of HIV blips
does not exist, and as a consequence the impact of HIV blips
remains an issue for debate.11-13
International clinical practice guidelines based onCMVvi-
ral loads remains 1 of the most elusive issues to solve in the
care of CMV in transplant recipients, even despite the intro-
duction of an international WHO calibration standard for
CMV PCR assays a couple of years ago.3 This is mainly due
to the multifaceted challenges surrounding all involved steps
FIGURE 4. Forest plot of HR [95%CI] for a first CMV infection after transplantation. *Time dependent variables were updated accordingly, and
death was included as a competing risk. The model also included age, sex, calendar year, and adjusted for type of transplantation (kidney, liver,
heart, lung, myeloablative conditioning transplantation, nonmyeloablative conditioning and umbilical cord blood transplantations). Compared
with kidney recipients, lung and umbilical cord blood transplantation recipients had an increased HR of subsequent CMV infection (lung
(HR, 1.5; 95% CI, 1.03-2.3; P = 0.03) and umbilical blood cord (HR, 4.3; 95% CI, 1.6-12.0; P = 0.004) respectively. **For solid organ trans-
plantation recipients CMV IgG D+/R- is associated with high risk of CMV infection, while D-/R+ is associated with low risk. Among bone marrow
transplant recipients, D-/R+ is associated with a high risk of CMV infection, whereas D+/R- is associated with a low risk. For both types of
transplantation, D+/R+ is associated with intermediary risk of CMV infection.
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in the in theCMVPCRassay procedures, that, if not standard-
ized and optimized, may cause inter and intra assay vari-
ability.4-6 The present study is performed on plasma samples,
using the same commercial assay over time, and the viral load
levels have been converted according to the WHO standard
for better interpretation of the results. As such, our results
can be extrapolated to other sites using a similar approach,
although it is recognized that interassay variability is a
limitation.4-7,23,24 Furthermore, if whole blood and not
plasma is used, it is likely that the epidemiology of CMV blips
may be different and should be explored in settings using
this approach.25
Our study does not address the most appropriate indica-
tion for when to commence antiviral therapy in patients with
CMV infection. We defined CMV infection (as opposed to
blips) conservatively. For example, if the first positive sample
measured 273 IU/mL, and the next sample also measured
273 IU/mL, the CMVPCR triplicate was considered evidence
of ongoing replication (Figure 1). Initiation of treatment in
such a patient, provided that he or she is asymptomatic,
may not be attractive to the clinician. Some studies would
argue that the viral load threshold for initiating antiviral
therapy is approximately 4000 IU/mL.26 However, of course,
application of any threshold value assumes that the patient is
suffering from CMV infection. Our data address the issue of
how to interpret the first positive CMV PCR in the course of
monitoring for emerging CMV infection. If the viral load is
low, blips are relatively frequent.
The clinical dilemma that our results pose is that clinicians
will only know that the first positive CMV PCRwas a blip in
hindsight (ie, until the next PCR is negative). However, we
have previously demonstrated that the viral doubling time
would allow confirming a positive CMV PCR of 910 IU/mL
or less within approximately 4 days without risking the viral
load of a potential infection reaching high levels.16 Therefore,
our data would suggest a recommendation to confirm low-
level CMV PCR results as soon as a positive result has been
generated before commencing antiviral therapy.
Some exceptions to this recommendation are well recog-
nized and include isolated CMV infection in the lung (typi-
cally seen in lung transplant recipients). In such patients,
CMV in plasma may be low (and undetectable in a significant
proportion of the patients), whereas the virus replicates and
cause disease in the lung compartment.27 Another exception
is the CMV gastrointestinal disease, which may not always be
associated with a positive CMV PCR signal in plasma/whole
blood.28,29 Finally, our results indicate that high-risk recipients
were less likely to experience blips compared to recipients
of intermediary/low risk CMV IgG serostatus. Therefore, in
these circumstances, the first low-level CMV PCR result may
prompt initiation of antiviral therapy before the results of a
confirmatory result becomes available.
We also found that CMV blips (1 or more) where the CMV
PCR signal was above 910 IU/mL was associated with excess
risk of subsequent genuine CMV infection, although we had
few patients with high cumulative viral load blips, resulting
in wider confidence intervals (Figure 4). The interpretation of
these findings is that CMV blips may equally reflect transient
low level CMV replication in some recipients perhaps due
to some level—although varying—immune control of repli-
cation. In support of this, the odds of a first positive CMV
PCR signal being a blip was higher in recipients with low to
intermediate risk CMV IgG serostatus reflecting prior expo-
sure to the infection. Conversely, lower viral load level blips
were not associated with subsequent excess risk, and hence
may reflect genuine false positive measurements generated
by the PCR technology.
In this study, we combined SOT and HSCT recipients to
improve power and assess the generalizability of the findings
across transplant types. Results derived from univariate
comparisons and after adjustment for potential confounders,
including transplant type (Table 2), were broadly consistent.
This indicates that the type of transplantation had little (if any)
impact on our main findings, even though it is of importance
to emphasize the associated heterogeneity that is introduced
when combining SOTandHSCT in the analyses. Interestingly,
use of anti-CMV therapy did also not impact our observa-
tions. These findings were consistent when restricting the anal-
ysis to triplicates observed without the recipient receiving any
anti-CMV therapy, indicating that CMV DNA detected in
plasma is reflecting release from cells likely outside the blood
compartment, and dynamic changes in CMV PCR in plasma
are protracted by the kinetic of release of CMV DNA from
these compartments. However, it should also be kept in mind
that the introduction of anti-CMV therapy was associated
with higher viral load in the indicator sample, which can
possibly also explain this lack of effect on the presence of
CMV blips.
In conclusion, we have demonstrated that CMV blips are
frequent while screening transplant recipients with plasma
CMV PCR, and in particular, if the viral load of the first
positive PCR is at the detection limit or the patient has
intermediary-/low-risk serostatus. These observations need
to be considered before initiation of anti-CMV treatment
based on first positive CMV PCR samples. Furthermore, the
cumulative viral load of CMV blips influence the risk of
CMV infection, indicating that the characteristics of CMV
blips may be important markers for subsequent infection
and that that CMV blips at least partly reflect transient
low-level CMV infection in transplant recipients. We encour-
age other clinics to apply the CMV PCR triplicate model to
their cohort data, to further validate the reproducibility of
this model.
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